Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thyroglobulin measurement is the most powerful outcome predictor in differentiated thyroid cancer: a decision tree analysis in a European multicenter series.
Giovanella L, Milan L, Roll W, Weber M, Schenke S, Kreissl M, Vrachimis A, Pabst K, Murat T, Petranović Ovčariček P, Campenni A, Görges R, Ceriani L. Giovanella L, et al. Among authors: pabst k. Clin Chem Lab Med. 2024 May 7;62(11):2307-2315. doi: 10.1515/cclm-2024-0405. Print 2024 Oct 28. Clin Chem Lab Med. 2024. PMID: 38706105
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.
Kessler L, Hirmas N, Pabst KM, Hamacher R, Ferdinandus J, Schaarschmidt BM, Milosevic A, Nader M, Umutlu L, Uhl W, Reinacher-Schick A, Lugnier C, Witte D, Niedergethmann M, Herrmann K, Fendler WP, Siveke JT. Kessler L, et al. Among authors: pabst km. J Nucl Med. 2023 Dec 1;64(12):1910-1917. doi: 10.2967/jnumed.122.264827. J Nucl Med. 2023. PMID: 37973185 Free article.
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.
Hirmas N, Hamacher R, Sraieb M, Ingenwerth M, Kessler L, Pabst KM, Barbato F, Lueckerath K, Kasper S, Nader M, Schildhaus HU, Kesch C, von Tresckow B, Hanoun C, Hautzel H, Aigner C, Glas M, Stuschke M, Kümmel S, Harter P, Lugnier C, Uhl W, Niedergethmann M, Hadaschik B, Grünwald V, Siveke JT, Herrmann K, Fendler WP. Hirmas N, et al. Among authors: pabst km. J Nucl Med. 2023 May;64(5):711-716. doi: 10.2967/jnumed.122.264689. Epub 2022 Dec 29. J Nucl Med. 2023. PMID: 36581374 Free article. Review.
Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma.
Hamacher R, Lanzafame H, Mavroeidi IA, Pabst KM, Kessler L, Cheung PF, Bauer S, Herrmann K, Schildhaus HU, Siveke JT, Fendler WP. Hamacher R, et al. Among authors: pabst km. PET Clin. 2023 Jul;18(3):361-367. doi: 10.1016/j.cpet.2023.02.008. Epub 2023 Mar 28. PET Clin. 2023. PMID: 36997366 Review.
Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer.
Giovanella L, Milan L, Roll W, Weber M, Schenke S, Kreissl M, Vrachimis A, Pabst K, Murat T, Petranovic Ovcaricek P, Riemann B, Ceriani L, Campenni A, Görges R. Giovanella L, et al. Among authors: pabst k. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2767-2774. doi: 10.1007/s00259-023-06239-8. Epub 2023 May 1. Eur J Nucl Med Mol Imaging. 2023. PMID: 37121981 Free PMC article.
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study.
Mei R, Kessler L, Pabst KM, Weber M, Schmidkonz C, Rischpler C, Zacho HD, Hope T, Schwarzenböck SM, Allen-Auerbach M, Emmett L, Ferdinandus J, Unterrainer M, Schaarschmidt BM, Umutlu L, Farolfi A, Castellucci P, Nanni C, Telo S, Fanti S, Herrmann K, Fendler WP. Mei R, et al. Among authors: pabst km. J Nucl Med. 2023 Jul;64(7):1043-1048. doi: 10.2967/jnumed.122.265245. Epub 2023 May 25. J Nucl Med. 2023. PMID: 37230530 Free article.
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.
Jeschke M, Ludwig JM, Leyh C, Pabst KM, Weber M, Theysohn JM, Lange CM, Herrmann K, Schmidt HH, Jochheim LS. Jeschke M, et al. Among authors: pabst km. Cancers (Basel). 2023 Aug 26;15(17):4274. doi: 10.3390/cancers15174274. Cancers (Basel). 2023. PMID: 37686549 Free PMC article.
Prognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.
Watanabe M, Fendler WP, Grafe H, Hirmas N, Hamacher R, Lanzafame H, Pabst KM, Hautzel H, Aigner C, Kasper S, von Tresckow B, Stuschke M, Kümmel S, Lugnier C, Hadaschik B, Grünwald V, Zarrad F, Siveke JT, Herrmann K, Weber M. Watanabe M, et al. Among authors: pabst km. J Nucl Med. 2024 Jul 1;65(7):1027-1034. doi: 10.2967/jnumed.123.266981. J Nucl Med. 2024. PMID: 38782454
102 results